Pitolisant Hydrochloride has 6 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Drugs That Prolong Qtc Interval, Mao Inhibitors. Patients taking Pitolisant Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 3
- Moderate
- 3
Major (3)
- Pitolisant Hydrochloride + Cyp3a Inducers— Decreases pitolisant exposure by 50%, potentially reducing efficacy. Dosage adjustment required.
- Pitolisant Hydrochloride + Drugs That Prolong Qtc Interval— Concomitant use may add to QT effects and increase risk of cardiac arrhythmia. Avoid combination.
- Pitolisant Hydrochloride + Mao Inhibitors— Concomitant administration increases pitolisant exposure by 2.2-fold. Reduce WAKIX dose by half.
Moderate (3)
- Pitolisant Hydrochloride + Ethinyl Estradiol— Hormonal contraceptive effectiveness may be reduced during and for 21 days after WAKIX discontinuation. Use alternative …
- Pitolisant Hydrochloride + Histamine— Centrally acting H1 receptor antagonists may reduce WAKIX effectiveness. Avoid centrally acting H1 receptor antagonists.
- Pitolisant Hydrochloride + Sensitive Cyp3a Substrates— WAKIX may reduce effectiveness of sensitive CYP3A4 substrates including hormonal contraceptives.